期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
基于优势肿瘤细胞分组的混合型肝癌的临床特征和预后研究
1
作者 张浩 李娟 +3 位作者 俞小炯 许建 董科 汪旭 《中国现代医学杂志》 CAS 2018年第22期68-73,共6页
目的回顾性分析不同优势肿瘤细胞分组的混合型肝癌(CHCC)的临床资料,探讨其临床特征和预后情况。方法收集CHCC病例的临床资料,按其瘤体内优势细胞类型分为3组:A组(HCC优势组18例)、B组(ICC优势组13例)、C组(混合组7例),比较各组病例的... 目的回顾性分析不同优势肿瘤细胞分组的混合型肝癌(CHCC)的临床资料,探讨其临床特征和预后情况。方法收集CHCC病例的临床资料,按其瘤体内优势细胞类型分为3组:A组(HCC优势组18例)、B组(ICC优势组13例)、C组(混合组7例),比较各组病例的临床特征及预后情况。结果 3组患者年龄、性别、乙肝或丙肝感染例数、肿瘤数目和直径、肝硬化、Child-Pugh分级等一般临床资料差异无统计学意义(P>0.05)。手术类型、脉管癌栓、门静脉/胆管受侵、卫星灶、淋巴结转移,以及术后免疫组织化学染色情况和AJCC分期等术中、术后资料差异无统计学意义(P>0.05)。术前A组AFP值高于B组和C组(P<0.0125)。术后1年各组无瘤生存率分别为42.1%、62.7%和45.7%,差异无统计学意义(P>0.05);1年总体生存率分别为69.3%、76.2%和68.6%,差异无统计学意义(P>0.05)。结论无论瘤体内优势肿瘤细胞比例有无差异,CHCC临床特征基本无差异,都是一种预后较差的恶性肿瘤,现阶段的首选治疗方法是大部分肝切除。 展开更多
关键词 混合型肝癌 优势肿瘤细胞 治疗 预后
下载PDF
Clinical Study on Suspension Pancreatic-Duct-Jejunum End-to-Side Continuous Suture Anastomosis in Pancreaticoduodenectomy 被引量:5
2
作者 Ke Dong Wei Xiong +1 位作者 xiao-jiong yu Chun Gu 《Chinese Medical Sciences Journal》 CAS CSCD 2013年第1期34-38,37-38,共5页
Objective To study the influence of Suspension Pancreatic-Duct-Jejunum End-to-Side Continuous Suture Anastomosis (SPDJCS) on the incidence of pancreatic fistula after pancreaticoduodenectomy, and to analyze its appl... Objective To study the influence of Suspension Pancreatic-Duct-Jejunum End-to-Side Continuous Suture Anastomosis (SPDJCS) on the incidence of pancreatic fistula after pancreaticoduodenectomy, and to analyze its applicability, safety, and efficacies. Methods A prospective controlled trial was conducted with 165 cases receiving pancreati- coduodenectomy in the Department of Hepatopancreatobiliary Surgery from January 2010 to May 2012. The patients were divided into Group A (end-to-end/end-to-side invaginated anastomosis, n=52), Group B (end-to-side mucosal anastomosis, n=48), and Group C (SPDJCS, n=65). The preoperative data, intra- operative data, and operative outcomes (incidence of pancreatic fistula, operation time, intraoperative blood loss, peritoneal drainage, peritoneal hemorrhage, peritoneal abscess, delayed gastric emptying, pulmonary infection, postoperative infection, blood transfusion, and perioperative mortality) were com- pared among the 3 groups. Results The total incidence of pancreatic fistula was 13.9% (23/165) in all the 165 patients. The inci- dence in Group A and Group B was 23.1% (12/52) and 18.8% (9/48), both higher than that in Group C [3.1% (2/65), both P〈0.05]. Group C showed significantly better outcomes than group A and B in terms of the opera- tion time (5.5±1.2 hours vs. 6.1±1.1 hours, 5.5±1.2 hours vs. 6.3±1.5 hours), volume of blood loss (412.0±205.0 mL vs. 525.0±217.0 mL, 412.0±205.0 mL vs. 514.0±217.0 mL), and postoperative drainage amount of plasma tubes (175.0±65.0 mE vs. 275.0±80.0 mL, 175.0±65.0 mL vs. 255.0±75.0 mL) (all P〈0.05), while Group A and Group B displayed no difference in these aspects (P〉0.05). As complications other than pancreatic fistula were concerned, the three groups were not different from each other (P〉0.05). Conclusions SPDJCS may have the effect of reducing the incidence of pancreatic fistula after pan- creaticoduodenectomy. It could be safe, practical and convenient technique of anastomosis for pancreaticoje- junostomy. 展开更多
关键词 PANCREATICODUODENECTOMY pancreatic fistula PANCREATICOJEJUNOSTOMY con- tinuous suture suspension of pancreatic duct
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部